share_log

復宏漢霖(02696.HK)「漢利康」新適應症補充申請獲批

Fohong Hanlin (02696.HK) Supplementary Application for “Hanlikang” New Indication Approved

即市頭條 ·  Jul 14, 2020 17:47

Hanlin (02696.HK) announced that the new application for supplemental indications for HLX01 products, HL (rituximab injection), was approved by the State Drug Administration. The company says it is expected to further expand the product indications and provide more options for domestic follicular lymphoma and chronic lymphocytic leukemia patients. (gc/a) ~

ASDAK Financial News

Website: www.aastocks.com

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment